SCHEMBL309993

SCHEMBL309993

CCOC(=O)c1cc(OCCO)c2ccn(C3CC3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 1/20 0.37
FDFT1 P37268 1/20 0.37
HSD17B2 P37059 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
PABPC1 P11940 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
VDR P11473 1/20 0.36
MAPT P10636 1/20 0.35
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308549 0.91 GLA (0.41) RAB9AALDH1A1MAPK1FDFT1HSD17B2
SCHEMBL309329 0.86 HSD17B10 (0.36) SMN1; SMN2GAAHPGDHSD17B10
SCHEMBL308949 0.86 HSD17B2 (0.48) RAB9AALDH1A1MAPK1HSD17B2CA12
SCHEMBL308824 0.84 ALDH1A1 (0.38) RAB9AALDH1A1MAPK1FDFT1HSD17B2
SCHEMBL308369 0.81 CA12 (0.48) RAB9AALDH1A1MAPK1FDFT1HSD17B2
SCHEMBL308422 0.80 TSHR (0.44) TSHRSMN1; SMN2GAAKMT2AMEN1
SCHEMBL731441 0.77 MAPT (0.40) ALDH1A1MAPK1CA12CA1CA2
SCHEMBL743989 0.72 AGTR1 (0.40) ALDH1A1MAPK1
SCHEMBL731518 0.72 ALDH1A1 (0.39) ALDH1A1MAPK1CA12CA1CA2
SCHEMBL14150097 0.72 ALDH1A1 (0.39) RAB9AALDH1A1MAPK1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111406-B1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK SHARP & DOHME (US) 2012-10-24 EP disclosed
US-8093389-B2 e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases MERCK SHARP & DOHME CORP. (US) 2012-01-10 US disclosed
US-20080171761-A1 Substituted spirochromanone derivatives MERCK SHARP & DOHME LLC 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171761-A1 Substituted spirochromanone derivatives CBR3, CBR1, CNKSR1 TSHR 283/4885RAB9A 2494/4885ALDH1A1 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.